Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.52
-1.68 (-4.91%)
At close: Nov 6, 2026, 4:00 PM EST
32.68
+0.16 (0.48%)
After-hours: Nov 6, 2026, 7:59 PM EST
Castle Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 377.13 | 344.23 | 332.07 | 219.79 | 137.04 | 94.09 | |
Revenue Growth | 9.78% | 3.66% | 51.09% | 60.38% | 45.65% | 50.18% |
Cost of Revenue | 86.47 | 71.03 | 60.21 | 44.98 | 32.01 | 15.82 |
Gross Profit | 290.66 | 273.2 | 271.86 | 174.81 | 105.03 | 78.26 |
Selling, General & Admin | 251.54 | 229.32 | 200.05 | 180.15 | 143 | 86.74 |
Research & Development | 58.29 | 51.85 | 52.04 | 53.62 | 44.9 | 29.65 |
Amortization of Goodwill & Intangibles | 8.86 | 14.74 | 11.11 | 9.01 | 8.27 | 1.96 |
Operating Expenses | 318.69 | 295.91 | 263.19 | 242.78 | 196.17 | 118.34 |
Operating Income | -28.04 | -22.71 | 8.67 | -67.98 | -91.14 | -40.08 |
Interest Expense | -0.55 | -0.09 | -0.58 | -0.01 | -0.02 | -0 |
Interest & Investment Income | 10.31 | 11.77 | 12.92 | 10.62 | 3.97 | 0.07 |
Currency Exchange Gain (Loss) | 0.14 | 0.14 | - | - | - | - |
Other Non Operating Income (Expenses) | -0.6 | - | - | - | - | - |
EBT Excluding Unusual Items | -18.73 | -10.88 | 21.01 | -57.37 | -87.19 | -40.01 |
Gain (Loss) on Sale of Investments | -3.89 | 1.47 | 0.56 | - | - | - |
Asset Writedown | - | -20.1 | - | - | - | - |
Other Unusual Items | - | - | - | - | 18.29 | - |
Pretax Income | -22.62 | -29.51 | 21.56 | -57.37 | -68.9 | -40.01 |
Income Tax Expense | 0.4 | -5.36 | 3.32 | 0.1 | -1.77 | -8.72 |
Net Income | -23.01 | -24.16 | 18.25 | -57.47 | -67.14 | -31.29 |
Net Income to Common | -23.01 | -24.16 | 18.25 | -57.47 | -67.14 | -31.29 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 30 | 29 | 28 | 27 | 26 | 25 |
Shares Outstanding (Diluted) | 30 | 29 | 29 | 27 | 26 | 25 |
Shares Change | 4.31% | -0.92% | 9.15% | 2.87% | 3.65% | 32.80% |
EPS (Basic) | -0.77 | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 |
EPS (Diluted) | -0.77 | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3.96 | 28.33 | 36.54 | -19.25 | -47.29 | -22.47 |
Free Cash Flow Per Share | 0.13 | 0.98 | 1.25 | -0.72 | -1.81 | -0.89 |
Gross Margin | 77.07% | 79.37% | 81.87% | 79.53% | 76.64% | 83.18% |
Operating Margin | -7.43% | -6.60% | 2.61% | -30.93% | -66.51% | -42.60% |
Profit Margin | -6.10% | -7.02% | 5.49% | -26.15% | -48.99% | -33.26% |
Free Cash Flow Margin | 1.05% | 8.23% | 11.00% | -8.76% | -34.51% | -23.88% |
EBITDA | -12.08 | -2.04 | 24.67 | -55.65 | -80.6 | -36.67 |
EBITDA Margin | -3.20% | -0.59% | 7.43% | -25.32% | -58.81% | -38.98% |
D&A For EBITDA | 15.96 | 20.67 | 16 | 12.33 | 10.54 | 3.41 |
EBIT | -28.04 | -22.71 | 8.67 | -67.98 | -91.14 | -40.08 |
EBIT Margin | -7.43% | -6.60% | 2.61% | -30.93% | -66.51% | -42.60% |
Effective Tax Rate | - | - | 15.39% | - | - | - |